Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Surmodics (SRDX)
NASDAQ:SRDX
Holding SRDX?
Track your performance easily
SRDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.17 - $42.44
Previous Close$39.33
Volume174.41K
Average Volume (3M)243.60K
Market Cap
$563.44M
Enterprise Value$552.88M
Total Cash (Recent Filing)$40.11M
Total Debt (Recent Filing)$29.55M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Jan 30, 2025EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding14,267,000
10 Day Avg. Volume205,983
30 Day Avg. Volume243,601
Standard Deviation0.16
R-Squared0.16
Alpha-0.00824
Financial Highlights & Ratios
Price to Book (P/B)4.73
Price to Sales (P/S)4.63
Price to Cash Flow (P/CF)-68.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.39
Enterprise Value/Gross Profit5.94
Enterprise Value/Ebitda187.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
SurModics News
PremiumCompany Announcements
Surmodics Inc. Reports Q4 and FY 2024 Results
PremiumCompany Announcements
Ronald B. Kalich Resigns from SurModics Board AmicablyBulls Say, Bears Say
Bulls Say
Financial PerformanceSurmodics’ Q4 financial results were quite strong relative to the modeling as well as the consensus, with total revenue of $33.2 million, a significant increase compared to the same period a year ago.
Improved Revenue GrowthSRDX's revenue growth, excluding SurVeil license fee revenue, improved to 17% in F4Q24 from 9% in F3Q24.
Medical Device Unit GrowthThe medical device unit accounted for $25.8 million in revenue, reflecting a substantial growth of 22.2%.
Bears Say
Acquisition DelayThe pending acquisition of Surmodics by GTCR has been delayed due to a request for additional information from the United States Federal Trade Commission, extending the waiting period.
Acquisition UncertaintyThere is a pending acquisition of SRDX by a private equity firm.
Regulatory RisksIf the GTCR transaction were ultimately blocked by the FTC, SRDX would be entitled to a regulatory termination fee, indicating potential complications in the acquisition process.
---
Ownership Overview
4.33% Insiders
18.27% Mutual Funds
32.82% Other Institutional Investors
31.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRDX FAQ
What was Surmodics’s price range in the past 12 months?
Surmodics lowest stock price was $25.17 and its highest was $42.44 in the past 12 months.
What is Surmodics’s market cap?
Currently, no data Available
When is Surmodics’s upcoming earnings report date?
Surmodics’s upcoming earnings report date is Jan 30, 2025 which is in 65 days.
How were Surmodics’s earnings last quarter?
Surmodics released its earnings results on Nov 06, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.293 by $0.163.
Is Surmodics overvalued?
According to Wall Street analysts Surmodics’s price is currently Overvalued.
Does Surmodics pay dividends?
Surmodics does not currently pay dividends.
What is Surmodics’s EPS estimate?
Surmodics’s EPS estimate is -$0.12.
How many shares outstanding does Surmodics have?
Surmodics has 14,326,000 shares outstanding.
What happened to Surmodics’s price movement after its last earnings report?
Surmodics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.293. Following the earnings report the stock price went up 2.204%.
Which hedge fund is a major shareholder of Surmodics?
Among the largest hedge funds holding Surmodics’s share is Gamco Investors, Inc. ET AL. It holds Surmodics’s shares valued at 6M.
---
SurModics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 19.8K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.13%
12-Months-Change
Fundamentals
Return on Equity
-9.67%
Trailing 12-Months
Asset Growth
-3.86%
Trailing 12-Months
Company Description
Surmodics
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.
---
SRDX Earnings Call
Q2 2024
0:00 / 0:00
---
SRDX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---